Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Jan-Feb 2015;21(1):42-51.
doi: 10.1111/tbj.12364. Epub 2014 Dec 22.

The Development of Dose-Dense Adjuvant Chemotherapy

Affiliations
Review

The Development of Dose-Dense Adjuvant Chemotherapy

Clifford Hudis et al. Breast J. .

Abstract

Dose-dense chemotherapy has made a significant contribution to the adjuvant treatment of breast cancer. One way of achieving dose-density is through the use of sequential therapy with noncross resistant therapies to cause cell kill in tumors composed of heterogeneous cells. Another way to achieve this is to shorten the inter-treatment interval to minimize the re-growth of tumor cells, thus allowing for more effective cell killing. Several trials have tested this concept with the majority demonstrating improved efficacy with a dose-density when compared with the traditional schedule. One such notable trial was CALGB 9741 that showed that when dose size and cycle numbers were kept constant, shortening the interval between each chemotherapy dose, with granulocyte-colony stimulating factor support, significantly improved disease-free and overall survival. This important and practice-changing trial led to the wide adoption of dose-dense chemotherapy and formed the basis of many subsequent studies, including allowing for the addition of biologic and targeted agents with excellent safety profile.

Keywords: adjuvant therapy; breast cancer; chemotherapy; dose-dense.

Similar articles

See all similar articles

Cited by 1 article

MeSH terms

Feedback